Home > Market > Market Stats > Sun pharmaceutical industries
  1. S&P BSE SENSEX
    53,895.56 1103.33 (2.09%)
  1. NIFTY 50 D
    Delayed by 15 mins

    16,172.6 363.2 (2.3%)
  1. NIFTY BANK D
    Delayed by 15 mins

    34,071.35 755.7 (2.27%)
  1. S&P BSE MIDCAP
    22,392.35 322.62 (1.46%)

SUN.BO Sun Pharmaceutical Industries - Share price

913.45 29.05 (3.28%) 20 MAY 2022 06:47:58
914.7 30.1 (3.4%) 20 May 2022 06:33:26
Add Stock to Portfolio / Watchlist on mint Genie + Add Stock
  1. Open price885.8
  2. Prev close884.4
  3. Day high915.0
  4. Day low885.8
  5. 52 week high966.9
  6. 52 week low652.75
  7. Bid quantity913.05
  8. Volume127126
  1. Open price893
  2. Prev close884.6
  3. Day high915
  4. Day low889.05
  5. 52 week high967.05
  6. 52 week low652.7
  7. Bid quantity914.45
  8. Volume1495608

Sun Pharmaceutical Industries Financials

Standalone
Revenue
33,498.14
Total Revenue
33,498.14
Costof Revenue Total
9,885.42
Gross Profit
23,612.72
Selling/ General/ Admin Expenses Total
14,344.76
Depreciation/ Amortization
2,079.95
Unusual Expense( Income)
4,321.69
Other Operating Expenses Total
526.81
Total Operating Expense
31,158.63
Operating Income
2,339.51
Interest Inc( Exp) Net- Non- Op Total
3,787
Gain( Loss)on Saleof Assets
138.8
Other Net
67.28
Net Income Before Taxes
2,799.37
Provisionfor Income Taxes
514.69
Net Income After Taxes
2,284.68
Minority Interest
631.47
Equity In Affiliates
-123.3
Net Income Before Extra Items
2,903.82
Net Income
2,903.82
Income Availableto Com Excl Extra Ord
2,903.82
Income Availableto Com Incl Extra Ord
2,903.82
Diluted Net Income
2,903.82
Diluted Weighted Average Shares
239.93
Diluted EPS Excluding Extra Ord Items
12.1
DPS- Common Stock Primary Issue
7.5
Diluted Normalized EPS
26.76
COMPANY INFORMATION
Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a range of generic formulations. It produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The Company offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The Company operates manufacturing sites across 6 continents.
Industry Biotechnology & Drugs
ISIN INE044A01036
BSE code 524715
NSE code SUNPHARMA
Chief Financial OfficerC. S.   Muralidharan
Chief Executive Officer - Taro Pharmaceutical Industries LimitedUday   Baldota
Chief Executive Officer, North AmericaAbhay   Gandhi
Chief Executive Officer - India BusinessKirti   Ganorkar
Chief Executive Officer - API BusinessAnilkumar   Jain
Executive Vice President, Global Head - QualityJila   Breeze
Executive Vice President, Head - Research and Development, USPradeep   Sanghvi
Executive Vice President, Head - Emerging Markets, Head - Global Generics, Research and Development, Business DevelopmentAalok   Shanghvi
Executive Vice President - Sun Global OperationsDavinder   Singh
Senior Vice President, Head of Human ResourcesSapna   Purohit
NEWS - Sun pharmaceutical industries
View More News
Recommended For You
×
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsFeedbackRedeem a Gift CardLogout